SMARTDM2 对比 DAPT Risk Calculator 的使用情况和统计数据

The management of outpatient antihyperglycemic regimens for patients with type 2 diabetes is complicated. This app is designed to synthesize treatment pathway guidelines developed by the American Diabetes Association, the American Association of Clinical Endocrinologists / American College of Endocrinology, and the Emory University Diabetes Council. Based on patient-specific factors that you select, a weighted list of medication options is sorted and presented. Designed for use by healthcare professionals. We have no relationship with nor has the app been endorsed by the American Diabetes Association, the American Association of Clinical Endocrinologists or the American College of Endocrinology. Results from the app should not be considered medical advice: individual patient factors not accounted for in the app may influence management decisions; medical evidence and guidelines may change ahead of updates to the app; regardless of best efforts, errors may be present in the app. Consult your doctor before making any changes to your medication regimen.
  • Apple 应用商店
  • 免费
  • 医疗

商店排名

- -

The DAPT Risk Calculator provides decision support for clinicians evaluating the continuation of DAPT therapy for patients at least 12 months post-PCI procedure, and the risk/benefit of continuing or discontinuing DAPT. The App provides a DAPT Risk Score as a numerical value between 0-9 and calculates the % of risk for three end points: stent thrombosis/ myocardial infraction (MI), major adverse cardiovascular and cerebrovascular event (MACCE), and bleeding.
  • Apple 应用商店
  • 免费
  • 医疗

商店排名

- -

SMARTDM2与DAPT Risk Calculator排名比较

对比 SMARTDM2 与 DAPT Risk Calculator 在过去 28 天内的排名趋势

排名

没有可用的数据

SMARTDM2 对比 DAPT Risk Calculator 的排名,按国家/地区比较

对比 SMARTDM2 与 DAPT Risk Calculator 在过去 28 天内的排名趋势

无数据可显示

通过免费试用版比较任何网站

开始使用
SMARTDM2 VS.
DAPT Risk Calculator

十二月 26, 2024